Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis

• DOI: 10.1186/s12879-018-3638-z
• Publication Date: 2019-01-03T12:01:32Z
• Authors: Noura M. Al-Mutairi; Suhail Ahmad; Eiman Mokaddas; Hanaa S. Eldeen; Susan Joseph
• Keywords: rpoB; INHA; Pyrazinamide

Accurate drug susceptibility testing (DST) of Mycobacterium tuberculosis in clinical specimens and culture isolates to first-line drugs is crucial for diagnosis management multidrug-resistant (MDR-TB). Resistance M. rifampicin mainly due mutations hot-spot region rpoB gene (HSR-rpoB). The prevalence disputed (generally missed by rapid phenotypic DST methods) mutations, which include L511P, D516Y, H526N, H526L, H526S, L533P HSR-rpoB I572F cluster II gene, largely unknown. This study determined the occurrence all at codon 572 strains phenotypically susceptible Kuwait. A total 242 were used. against was performed Mycobacteria growth indicator tube (MGIT) 960 system. Mutations (and katG 315 inhA-regulatory isoniazid resistance) detected GenoType MDBDRplus assay. mutation developing a multiplex allele-specific (MAS)-PCR Results confirmed PCR-sequencing respective loci. Molecular detection resistance ethambutol pyrazinamide fingerprinting spoligotyping also with an mutation. Among rifampicin-susceptible isolates, 0 130 pansusceptible/monodrug-resistant but 4 112 polydrug-resistant contained All resistant molecular screening identified additional one isolate each. In final analysis, 2 drugs. Spoligotyping showed that belonged different lineages. Four (1.7%) including four least (MDR-TB) suggests should be checked genotypic optimal patient since failure/relapse rates are nearly same canonical or